Remembering Martine Van Glabbeke: EORTC Leader in Cancer Trial Design

Martine Van Glabbeke was a pivotal figure in oncology clinical research, renowned for her expertise in biostatistics and her leadership within the European Organisation for Research and Treatment of Cancer (EORTC). Her contributions significantly advanced the design and analysis of cancer trials, particularly in the field of gastrointestinal stromal tumors (GIST). As a long-time collaborator with EORTC’s data center and statistical methodologies team, she played a critical role in shaping evidence-based approaches to cancer treatment evaluation.

Her work was instrumental in the landmark Intergroup EORTC-ISG-AGITG Phase III trial, which established that absence of tumor progression, as measured by Response Evaluation Criteria in Solid Tumors (RECIST), is a strong predictor of survival in patients with advanced GIST treated with imatinib mesylate. This finding transformed clinical monitoring practices, emphasizing progression-free survival as a key endpoint in targeted cancer therapies.

Contributions to GIST Research and Clinical Trial Methodology

Van Glabbeke’s statistical expertise was central to interpreting complex oncology trial data. In the 2009 study published in the Journal of Clinical Oncology, she co-authored the analysis demonstrating that patients with advanced GIST who showed no tumor progression on imatinib had significantly better long-term outcomes. This insight helped validate the apply of molecularly targeted therapies and reinforced the importance of early, objective tumor assessment in clinical practice.

Her collaboration with leading oncologists and researchers across Europe and beyond exemplified EORTC’s mission to foster multinational, interdisciplinary cancer research. Through her work, she helped ensure that clinical trials were not only scientifically rigorous but also clinically meaningful, bridging the gap between statistical analysis and patient outcomes.

Legacy in Oncology Research

Martine Van Glabbeke’s influence extended beyond individual studies. As a trusted biostatistician within EORTC, she contributed to the development of robust trial frameworks that continue to inform cancer research today. Her emphasis on methodological precision and real-world applicability elevated the standards of oncology clinical investigation.

Colleagues remember her as a meticulous scientist, a collaborative partner and a quiet force behind some of the most impactful cancer trials of the early 21st century. Her legacy endures in the continued use of RECIST criteria and progression-free survival as pivotal metrics in cancer drug development and regulatory decision-making.

Frequently Asked Questions